Neoadjuvant Therapy in Differentiated Thyroid Cancer

Table 5

Molecular targets of the TKIs sorafenib, lenvatinib, and pazopanib.

Drug	Targets
Sorafenib	Raf kinase, VEGFR1–3, PDGFRβ, RET [27].
Lenvatinib	VEGFR1–3, FGFR1–4, RET, c-Kit, PDGFRβ [28].
Pazopanib	VEGFRs, PDGFR, c-Kit [29, 30].

Definitions: FGFR: fibroblast growth factor receptor, PDGFR: platelet derived growth factor receptor, TKI: tyrosine kinase inhibitor, and VEGFR: vascular endothelial growth factor receptor.